[go: up one dir, main page]

PE20090365A1 - Imidazopirazinas como inhibidores de proteina quinasa - Google Patents

Imidazopirazinas como inhibidores de proteina quinasa

Info

Publication number
PE20090365A1
PE20090365A1 PE2008001001A PE2008001001A PE20090365A1 PE 20090365 A1 PE20090365 A1 PE 20090365A1 PE 2008001001 A PE2008001001 A PE 2008001001A PE 2008001001 A PE2008001001 A PE 2008001001A PE 20090365 A1 PE20090365 A1 PE 20090365A1
Authority
PE
Peru
Prior art keywords
cr7r8
imidazopyrazines
nr5r6
ethyl
protein kinase
Prior art date
Application number
PE2008001001A
Other languages
English (en)
Inventor
David B Belanger
Angela D Kerekes
Zhaoyang Meng
Jayram R Tagat
Sara J Esposite
Yushi Xiao
Bheemashankar K Kulkarni
Yonglian Zhang
Patrick J Curran
Ronald J Doll
Tao Yu
Amit K Mandal
M Arshad Siddiqui
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40002934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090365(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090365A1 publication Critical patent/PE20090365A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE IMIDAZOPIRAZINAS DE FORMULA I, EN EL QUE R ES H, CN, -NR5R6, -N(R5)C(O)R6, ENTRE OTROS; R1 ES H, FLUOR, FENILO, TETRAHIDROISOQUINOLILO, ENTRE OTROS; R2 ES H, 2-FENETILO, 1,2,4-TIADIAZOLILO, BENZOFURAZANILO, ENTRE OTROS; R3 ES HETEROCICLIL-(CR7R8)n-X, HETEROCICLENIL-(CR7R8)n-X, HETEROARIL-(CR7R8)n-X O ARIL-(CR7R8)n-X; n ES DE 1 A 6; X ES -NR5R6, -OR5, SO2R5, ENTRE OTROS; R7 Y R8 SON H, ETILO, n-PROPILO, NAFTILO, CICLOHEXILMETILO, ENTRE OTROS; R5 ES ISOPROPILO, ETIL-SH, PIPERIDINILMETILO, ENTRE OTROS; R6 ES PIRROLIDINONA, 2-PIRIDINILMETILO, 2-NAFTALENMETOXI, FENOXICARBONILO, ENTRE OTROS. SON SELECCIONADOS II, III, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y COMPOSICION FARMACEUTICA CON UN SEGUNDO COMPONENTE ADICIONAL, TAL COMO CITARABINA, DOCETAXEL, TESTOLACTONA, RITUXIMAB, ENTRE OTROS. DICHOS COMPUESTOS SON MODULADORES DE PROTEINQUINASA MEDIANTE LA INHIBICION DE UNA AURORA QUINASA, POR LO QUE SON DE UTILIDAD EN PROCESOS DE HIPERPROLIFERACION CELULAR Y/O CANCER
PE2008001001A 2007-06-14 2008-06-11 Imidazopirazinas como inhibidores de proteina quinasa PE20090365A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94399907P 2007-06-14 2007-06-14
US98793207P 2007-11-14 2007-11-14

Publications (1)

Publication Number Publication Date
PE20090365A1 true PE20090365A1 (es) 2009-04-04

Family

ID=40002934

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001001A PE20090365A1 (es) 2007-06-14 2008-06-11 Imidazopirazinas como inhibidores de proteina quinasa

Country Status (10)

Country Link
EP (1) EP2170892A2 (es)
JP (1) JP2010529195A (es)
CN (1) CN101772500A (es)
AR (1) AR066958A1 (es)
CA (1) CA2690557A1 (es)
CL (1) CL2008001745A1 (es)
MX (1) MX2009013729A (es)
PE (1) PE20090365A1 (es)
TW (1) TW200911811A (es)
WO (1) WO2008156614A2 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2419429T3 (da) 2009-04-16 2014-06-23 Ct Nac De Investigaciones Oncológicas Cnio Imidazopyraziner som inhibitorer af proteinkinaser
TW201107329A (en) * 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2473041B1 (en) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
KR101774035B1 (ko) 2009-10-30 2017-09-01 얀센 파마슈티카 엔.브이. 이미다조［１，２―ｂ］피리다진 유도체 및 ＰＤＥ１０ 저해제로서의 그의 용도
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
EP2576560B1 (en) * 2010-06-01 2015-09-30 Bayer Intellectual Property GmbH Substituted imidazopyrazines
DK2630259T3 (en) * 2010-10-20 2015-07-06 Univ Bordeaux SIGNATURES OF CLINICAL OUTCOME In gastrointestinal stromal tumors AND METHOD FOR THE TREATMENT OF gastrointestinal stromal tumors
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
EP2444084A1 (en) 2010-10-21 2012-04-25 Centro Nacional de Investigaciones Oncológicas (CNIO) Use of PI3K inibitors for the treatment of obesity
WO2012080230A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US8673905B2 (en) * 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
JP2014521595A (ja) 2011-05-25 2014-08-28 ブリストル−マイヤーズ スクイブ カンパニー 抗アポトーシスＢｃｌ阻害剤として有用な置換スルホンアミド
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
JP6426603B2 (ja) 2012-06-26 2018-11-21 ヤンセン ファーマシューティカ エヌ．ベー． 神経障害または代謝障害の治療に使用するための、１−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］−キノキサリン化合物などのＰＤＥ２阻害剤とＰＤＥ１０阻害剤との組合せ
EP2869822B1 (en) 2012-07-09 2016-09-14 Janssen Pharmaceutica, N.V. Inhibitors of phosphodiesterase 10 enzyme
EP3466955B1 (en) 2014-01-13 2020-12-16 Aurigene Discovery Technologies Limited Method of preparing oxazolo[4,5-b]pyridine and thiazolo[4,5-b]pyridine derivatives as irak4 inhibitors for treating cancer
SG10201806849WA (en) 2014-02-13 2018-09-27 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
CN106488915B (zh) 2014-02-13 2020-10-02 因赛特公司 作为lsd1抑制剂的环丙胺
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
UA126277C2 (uk) 2015-08-12 2022-09-14 Інсайт Корпорейшн Солі інгібітору lsd1
BR112018071585B1 (pt) 2016-04-22 2024-01-02 Incyte Corporation Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
NZ796735A (en) 2017-02-06 2025-12-19 Univ Case Western Reserve Compositions and methods of modulating short-chain dehydrogenase activity
BR112019018991A2 (pt) * 2017-03-31 2020-04-14 Aurigene Discovery Technologies Limited compostos e composições para tratar distúrbios hematológicos
CN107954977A (zh) * 2017-12-15 2018-04-24 上海鼎雅药物化学科技有限公司 雷替曲塞中间体的合成方法
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN120463720A (zh) 2018-11-21 2025-08-12 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
JP7771084B2 (ja) * 2020-04-29 2025-11-17 エフ． ホフマン－ラ ロシュ アーゲー 抗菌８－フェニルアミノ－３－（ピラゾール－４－イル）イミダゾ［１，２－ａ］ピラジン誘導体
JP7758369B2 (ja) * 2020-07-10 2025-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｇａｓ４１阻害剤及びその使用方法
US12178821B2 (en) 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer
CN115702156A (zh) * 2021-04-23 2023-02-14 南京明德新药研发有限公司 吡啶酰胺类化合物
WO2023169438A1 (zh) * 2022-03-07 2023-09-14 上海凌达生物医药有限公司 一类含氮杂环类细胞周期抑制剂化合物、制备方法和用途
WO2024088192A1 (en) * 2022-10-26 2024-05-02 Js Innopharm (Suzhou) Ltd. An aurora a inhibitor for use in treatments of cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
EP1543008B1 (en) * 2002-09-23 2007-11-07 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
WO2006053121A2 (en) * 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
BRPI0618520A2 (pt) * 2005-11-10 2011-09-06 Schering Corp imidazopirazinas como inibidores de proteìna cinase

Also Published As

Publication number Publication date
TW200911811A (en) 2009-03-16
CN101772500A (zh) 2010-07-07
MX2009013729A (es) 2010-01-25
WO2008156614A3 (en) 2009-02-12
CA2690557A1 (en) 2008-12-24
CL2008001745A1 (es) 2008-12-05
AR066958A1 (es) 2009-09-23
JP2010529195A (ja) 2010-08-26
WO2008156614A2 (en) 2008-12-24
EP2170892A2 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
PE20090365A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
PE20210128A1 (es) Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
PE20080928A1 (es) Derivados de anilinopiperazina como inhibidores de proteina quinasa
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200970140A1 (ru) Производные и аналоги n-этилхинолонов и n-этилазахинолонов
DK1987038T3 (da) HCV NS5B-hæmmere
ECSP088367A (es) Derivados de bifenilo y su uso en el tratamiento de la hepatitis c
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
BRPI0915084B8 (pt) composto, e, composição farmacêutica
PE20071061A1 (es) Derivados de carbonilo como inhibidores de peptidil-deformilasa (pdf)
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
GT201100181A (es) "inhibidores de proteina cinasa"
CL2009000619A1 (es) Compuestos derivados de carbazol, inhibidores de la proteina hsp90; procedimiento para preparar los compuestos; compuestos intermediarios, composicion farmaceutica que comprende a uno de los compuestos; y el uso de los compuestos en el tratamiento del cancer.
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
MX2007016324A (es) Inhibidores hcv.
DE602007006796D1 (de) Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
EA200870164A1 (ru) Лечение вирусного гепатита
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.

Legal Events

Date Code Title Description
FC Refusal